Latest Us Operations News

MedAdvisor Limited has received a non-binding offer from a major multinational software company to acquire its ANZ business division, valuing it above current market expectations.

Gale Pacific has sharply downgraded its full-year EBITDA guidance due to tariff-driven demand softness in the US, while its Australia, New Zealand, and developing markets hold steady.

City Chic Collective faces a challenging US market due to steep tariff hikes on Chinese imports, prompting a strategic pause on new stock and a revised FY25 revenue outlook. Meanwhile, its ANZ operations continue robust growth, balancing the Group’s overall performance.

TZ Limited reported a challenging Q3 FY2025 with a $1.03 million net cash outflow amid US tariff disruptions but strengthened its SaaS base through the Keyvision acquisition, positioning for a rebound and growth in FY2026.

Stonehorse Energy’s Q1 2025 report reveals Canadian wells outperforming production forecasts while revenue dips due to softer commodity prices. US operations show recovery, and the company intensifies Canadian business development amid market volatility.

Hydralyte North America reported a 16% rise in Q1 FY25 net sales and improved gross margins, supported by a strategic capital raise and upcoming product launches targeting brain and gut health.

Control Bionics reports its strongest US revenue in years alongside Australia’s best quarter since 2022, propelled by new product launches and strategic investments.

Pacific Edge’s Cxbladder Plus and Triage 1 diagnostic tests are set for significant Medicare reimbursement increases, potentially reshaping the company’s US market prospects.

Change Financial Limited delivered a record Q3 FY25 revenue of US$3.9 million, driven by strong growth in its Payments as a Service platform and recurring revenue streams, while substantially completing its US operations exit. The company is confident of surpassing 30% revenue growth and achieving its first underlying EBITDA positive result for FY25.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

FBR Limited’s exclusive joint venture option with CRH Ventures for its Wall as a Service® offering in the US has expired without exercise, freeing the company to pursue independent financing and partnerships across key American markets.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.